Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Abstract Non‐alcoholic fatty liver disease (NAFLD) is strongly associated with obesity and may progress to non‐alcoholic steatohepatitis (NASH) and liver fibrosis. The deficit of pharmacological therapies for the latter mainly results from an incomplete understanding of involved pathological mechani...
Saved in:
| Main Authors: | Tenagne D Challa, Stephan Wueest, Fabrizio C Lucchini, Mara Dedual, Salvatore Modica, Marcela Borsigova, Christian Wolfrum, Matthias Blüher, Daniel Konrad |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-06-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201810124 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
by: Xue Wang, et al.
Published: (2025-01-01) -
Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy
by: Zhuomiao Lin, et al.
Published: (2025-01-01) -
Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH
by: Jianhua Zhang, et al.
Published: (2025-04-01) -
Unveiling Resmetirom: A systematic review and meta‐analysis on its impact on liver function and safety in non‐alcoholic steatohepatitis treatment
by: Hashim Talib Hashim, et al.
Published: (2024-10-01) -
A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease
by: Hao L, et al.
Published: (2025-01-01)